256 related articles for article (PubMed ID: 34007050)
21. PIM Kinase Inhibitors Block the Growth of Primary T-cell Acute Lymphoblastic Leukemia: Resistance Pathways Identified by Network Modeling Analysis.
Lim JT; Singh N; Leuvano LA; Calvert VS; Petricoin EF; Teachey DT; Lock RB; Padi M; Kraft AS; Padi SKR
Mol Cancer Ther; 2020 Sep; 19(9):1809-1821. PubMed ID: 32753387
[TBL] [Abstract][Full Text] [Related]
22. Comprehensive analysis of T cell leukemia signals reveals heterogeneity in the PI3 kinase-Akt pathway and limitations of PI3 kinase inhibitors as monotherapy.
Ksionda O; Mues M; Wandler AM; Donker L; Tenhagen M; Jun J; Ducker GS; Matlawska-Wasowska K; Shannon K; Shokat KM; Roose JP
PLoS One; 2018; 13(5):e0193849. PubMed ID: 29799846
[TBL] [Abstract][Full Text] [Related]
23. PSEN1-selective gamma-secretase inhibition in combination with kinase or XPO-1 inhibitors effectively targets T cell acute lymphoblastic leukemia.
Govaerts I; Prieto C; Vandersmissen C; Gielen O; Jacobs K; Provost S; Nittner D; Maertens J; Boeckx N; De Keersmaecker K; Segers H; Cools J
J Hematol Oncol; 2021 Jun; 14(1):97. PubMed ID: 34167562
[TBL] [Abstract][Full Text] [Related]
24. Paclitaxel induces prolonged activation of the Ras/MEK/ERK pathway independently of activating the programmed cell death machinery.
Okano J ; Rustgi AK
J Biol Chem; 2001 Jun; 276(22):19555-64. PubMed ID: 11278851
[TBL] [Abstract][Full Text] [Related]
25. Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers.
Kotani H; Adachi Y; Kitai H; Tomida S; Bando H; Faber AC; Yoshino T; Voon DC; Yano S; Ebi H
Oncogene; 2018 Mar; 37(13):1775-1787. PubMed ID: 29348459
[TBL] [Abstract][Full Text] [Related]
26. ERK inhibition overcomes acquired resistance to MEK inhibitors.
Hatzivassiliou G; Liu B; O'Brien C; Spoerke JM; Hoeflich KP; Haverty PM; Soriano R; Forrest WF; Heldens S; Chen H; Toy K; Ha C; Zhou W; Song K; Friedman LS; Amler LC; Hampton GM; Moffat J; Belvin M; Lackner MR
Mol Cancer Ther; 2012 May; 11(5):1143-54. PubMed ID: 22402123
[TBL] [Abstract][Full Text] [Related]
27. Loss of oncogenic Notch1 with resistance to a PI3K inhibitor in T-cell leukaemia.
Dail M; Wong J; Lawrence J; O'Connor D; Nakitandwe J; Chen SC; Xu J; Lee LB; Akagi K; Li Q; Aster JC; Pear WS; Downing JR; Sampath D; Shannon K
Nature; 2014 Sep; 513(7519):512-6. PubMed ID: 25043004
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia.
Spartà AM; Bressanin D; Chiarini F; Lonetti A; Cappellini A; Evangelisti C; Evangelisti C; Melchionda F; Pession A; Bertaina A; Locatelli F; McCubrey JA; Martelli AM
Cell Cycle; 2014; 13(14):2237-47. PubMed ID: 24874015
[TBL] [Abstract][Full Text] [Related]
29. IL-7R is essential for leukemia-initiating cell activity of T-cell acute lymphoblastic leukemia.
González-García S; Mosquera M; Fuentes P; Palumbo T; Escudero A; Pérez-Martínez A; Ramírez M; Corcoran AE; Toribio ML
Blood; 2019 Dec; 134(24):2171-2182. PubMed ID: 31530562
[TBL] [Abstract][Full Text] [Related]
30. Single-cell profiling of pediatric T-cell acute lymphoblastic leukemia: Impact of PTEN exon 7 mutation on PI3K/Akt and JAK-STAT signaling pathways.
Bonaccorso P; Bugarin C; Buracchi C; Fazio G; Biondi A; Lo Nigro L; Gaipa G
Cytometry B Clin Cytom; 2020 Nov; 98(6):491-503. PubMed ID: 32479694
[TBL] [Abstract][Full Text] [Related]
31. JAK3 mutations and mitochondrial apoptosis resistance in T-cell acute lymphoblastic leukemia.
Bodaar K; Yamagata N; Barthe A; Landrigan J; Chonghaile TN; Burns M; Stevenson KE; Devidas M; Loh ML; Hunger SP; Wood B; Silverman LB; Teachey DT; Meijerink JP; Letai A; Gutierrez A
Leukemia; 2022 Jun; 36(6):1499-1507. PubMed ID: 35411095
[TBL] [Abstract][Full Text] [Related]
32. T-cell acute lymphoblastic leukemia displays autocrine production of Interleukin-7.
Buffière A; Uzan B; Aucagne R; Hermetet F; Mas M; Nassurdine S; Aznague A; Carmignac V; Tournier B; Bouchot O; Ballerini P; Barata JT; Bastie JN; Delva L; Pflumio F; Quéré R
Oncogene; 2019 Nov; 38(48):7357-7365. PubMed ID: 31417180
[TBL] [Abstract][Full Text] [Related]
33. Anti-leukaemic activity of the TYK2 selective inhibitor NDI-031301 in T-cell acute lymphoblastic leukaemia.
Akahane K; Li Z; Etchin J; Berezovskaya A; Gjini E; Masse CE; Miao W; Rocnik J; Kapeller R; Greenwood JR; Tiv H; Sanda T; Weinstock DM; Look AT
Br J Haematol; 2017 Apr; 177(2):271-282. PubMed ID: 28295194
[TBL] [Abstract][Full Text] [Related]
34. Synergism between IL7R and CXCR4 drives BCR-ABL induced transformation in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Abdelrasoul H; Vadakumchery A; Werner M; Lenk L; Khadour A; Young M; El Ayoubi O; Vogiatzi F; Krämer M; Schmid V; Chen Z; Yousafzai Y; Cario G; Schrappe M; Müschen M; Halsey C; Mulaw MA; Schewe DM; Hobeika E; Alsadeq A; Jumaa H
Nat Commun; 2020 Jun; 11(1):3194. PubMed ID: 32581241
[TBL] [Abstract][Full Text] [Related]
35. Proteomics of resistance to Notch1 inhibition in acute lymphoblastic leukemia reveals targetable kinase signatures.
Franciosa G; Smits JGA; Minuzzo S; Martinez-Val A; Indraccolo S; Olsen JV
Nat Commun; 2021 May; 12(1):2507. PubMed ID: 33947863
[TBL] [Abstract][Full Text] [Related]
36. Superantigen-induced corticosteroid resistance of human T cells occurs through activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (MEK-ERK) pathway.
Li LB; Goleva E; Hall CF; Ou LS; Leung DY
J Allergy Clin Immunol; 2004 Nov; 114(5):1059-69. PubMed ID: 15536411
[TBL] [Abstract][Full Text] [Related]
37. Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma.
McNeill RS; Canoutas DA; Stuhlmiller TJ; Dhruv HD; Irvin DM; Bash RE; Angus SP; Herring LE; Simon JM; Skinner KR; Limas JC; Chen X; Schmid RS; Siegel MB; Van Swearingen AED; Hadler MJ; Sulman EP; Sarkaria JN; Anders CK; Graves LM; Berens ME; Johnson GL; Miller CR
Neuro Oncol; 2017 Oct; 19(11):1469-1480. PubMed ID: 28379424
[TBL] [Abstract][Full Text] [Related]
38. The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL).
Gazi M; Moharram SA; Marhäll A; Kazi JU
Cancer Lett; 2017 Apr; 392():9-16. PubMed ID: 28159681
[TBL] [Abstract][Full Text] [Related]
39. Effect of Tissue Transglutaminase on Steroid Resistance in T-Cell Acute Lymphoblastic Leukemia.
Jung HJ; Han EH; Jang IK; Yoon SH; Park JE
Anticancer Res; 2019 Nov; 39(11):6165-6173. PubMed ID: 31704844
[TBL] [Abstract][Full Text] [Related]
40. [P38 mitogen-activated protein kinase mediates glucocorticoid receptor function induced by dexamethasone in acute lymphoblastic leukemia cells].
He L; Li D; Hou KZ; Liu YP
Zhonghua Er Ke Za Zhi; 2007 Sep; 45(9):687-91. PubMed ID: 18021564
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]